JP2001516721A - 免疫応答の調節 - Google Patents

免疫応答の調節

Info

Publication number
JP2001516721A
JP2001516721A JP2000511505A JP2000511505A JP2001516721A JP 2001516721 A JP2001516721 A JP 2001516721A JP 2000511505 A JP2000511505 A JP 2000511505A JP 2000511505 A JP2000511505 A JP 2000511505A JP 2001516721 A JP2001516721 A JP 2001516721A
Authority
JP
Japan
Prior art keywords
group
compound
animal
alkyl
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000511505A
Other languages
English (en)
Japanese (ja)
Inventor
ランダウアー，カール，ジョン
プリーズ，ガブリエル，ヨハネス デュ
シラック，フォルカー，ラインハート
アットフィールド，デリック，セシル
デン ボガーデン，ヨハネス，ベイヤース ファン
Original Assignee
フランゴールド ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フランゴールド ホールディングス リミテッド filed Critical フランゴールド ホールディングス リミテッド
Publication of JP2001516721A publication Critical patent/JP2001516721A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000511505A 1997-09-16 1998-09-16 免疫応答の調節 Pending JP2001516721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA978319 1997-09-16
ZA97/8319 1997-09-16
PCT/US1998/019126 WO1999013885A1 (fr) 1997-09-16 1998-09-16 Modulation de reactions immunitaires

Publications (1)

Publication Number Publication Date
JP2001516721A true JP2001516721A (ja) 2001-10-02

Family

ID=25586589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000511505A Pending JP2001516721A (ja) 1997-09-16 1998-09-16 免疫応答の調節

Country Status (10)

Country Link
EP (1) EP1019063A4 (fr)
JP (1) JP2001516721A (fr)
CN (1) CN1279612A (fr)
AU (1) AU737867B2 (fr)
BR (1) BR9812321A (fr)
CA (1) CA2304119A1 (fr)
IL (1) IL135091A0 (fr)
NO (1) NO20001341L (fr)
NZ (1) NZ503418A (fr)
WO (1) WO1999013885A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324631A1 (fr) * 2000-10-26 2002-04-26 Virodene Pharmaceutical Holdings (Proprietary) Limited Substance ou composition pour le traitement du cancer
AP2006003648A0 (en) * 2003-12-05 2006-06-30 Namibia Medical Invest Pty Ltd Patch

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814659A (en) * 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition

Also Published As

Publication number Publication date
WO1999013885A1 (fr) 1999-03-25
CA2304119A1 (fr) 1999-03-25
IL135091A0 (en) 2001-05-20
NO20001341L (no) 2000-05-16
AU9389098A (en) 1999-04-05
NZ503418A (en) 2001-02-23
EP1019063A4 (fr) 2003-09-03
NO20001341D0 (no) 2000-03-15
CN1279612A (zh) 2001-01-10
EP1019063A1 (fr) 2000-07-19
AU737867B2 (en) 2001-09-06
BR9812321A (pt) 2000-09-05

Similar Documents

Publication Publication Date Title
Kaufman Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine
US20110020279A1 (en) Rabies cure
JP2004518653A (ja) 不安障害を治療する方法
Wang et al. Role of hypoxia‑inducible factor‑1α in autophagic cell death in microglial cells induced by hypoxia
TW201038544A (en) Anti-neurodegenerative diseases agents
Wu et al. Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice
Kiss Bimbova et al. Activation of three major signaling pathways after endurance training and spinal cord injury
Kimura et al. The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation
ES2948767T3 (es) Moléculas orgánicas pequeñas para uso en el tratamiento de trastornos neuroinflamatorios
JP2001516721A (ja) 免疫応答の調節
US20040248984A1 (en) Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
WO2023019846A1 (fr) Utilisation d'une neurotoxine cobra et sa préparation dans la préparation d'un médicament pour la prévention et le traitement de la maladie de parkinson
JP2002517456A (ja) 虚血からのニューロンの保護
CN105189449A (zh) 非肽bdnf神经营养蛋白模拟物
CN105311636B (zh) 一种抗疱疹病毒软膏剂及其制备方法
AU2022201835A1 (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
Margolis et al. Treatment of acute gouty arthritis with pituitary adrenocorticotropic hormone (ACTH)
Bodenham Death after flumazenil.
JP7359377B2 (ja) オキシトシン産生促進剤
US3433875A (en) The improvement of mental performance with potassium n-acetyl dl aminosuccinate
CN115300507B (zh) I-brd9作为arih1激动剂的用途
JP2017002043A (ja) 神経損傷治療又は予防用医薬
ES2303441A1 (es) Uso del acido valproico o de una sal farmaceuticamente aceptable del mismo para la prevencion y/o el tratamiento de la adenoleucodistrofia ligada a x.
RU2120297C1 (ru) Способ нормализации обменных процессов в клетке и препарат для этих целей

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100201